Danazol in refractory autoimmune thrombocytopenic purpura (ATP). A new therapeutic sequence.

R Ambríz-Fernández; G Chávez-Sánchez; J Pizzuto-Chávez; Morales-Polanco Mr; A Avilés-Miranda

Danazol in refractory autoimmune thrombocytopenic purpura (ATP). A new therapeutic sequence.

R Ambríz-Fernández, G Chávez-Sánchez, J Pizzuto-Chávez, Morales-Polanco Mr, A Avilés-Miranda

In: Archivos de investigacion medica · 1986 · vol. 16(3) , pp. 295–304 · PMID:3833096 · W2408764714

article OA: closed CC0 ⤵ 1 in-corpus citation

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

This paper investigates the efficacy of danazol in a new therapeutic sequence for patients with refractory autoimmune thrombocytopenic purpura.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Long-Term Danazol Therapy in Autoimmune Thrombocytopenia: Unmaintained Remission and Age-Dependent Response in Women 1989

Cited by (1)

Long-Term Danazol Therapy in Autoimmune Thrombocytopenia: Unmaintained Remission and Age-Dependent Response in Women 1989

Source provenance

openalex: last seen: 2026-05-10T10:46:03.109450+00:00

License: CC0 · commercial use OK